Roivant Sciences Q4 2024 GAAP EPS $(0.19) Beats $(0.32) Estimate, Sales $28.930M Miss $32.101M Estimate
Portfolio Pulse from Benzinga Newsdesk
Roivant Sciences (NASDAQ:ROIV) reported Q4 2024 GAAP EPS of $(0.19), beating the estimate of $(0.32). However, sales of $28.930M missed the $32.101M estimate.
May 30, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Roivant Sciences reported a better-than-expected EPS of $(0.19) for Q4 2024, beating the $(0.32) estimate. However, sales of $28.930M missed the $32.101M estimate.
The better-than-expected EPS is a positive sign, but the miss on sales could offset this. The mixed results may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100